Anakinra knee injections after an ACL injury to help prevent later osteoarthritis
Tests anakinra injected into the knee soon after an ACL injury.
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Biologic Therapy to Prevent Osteoarthritis After ACL Injury
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 32 people, planned
- Started
- 15 Sept 2021
- Expected to end
- 30 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Anakinra injection
- sterile saline injection
- Record updated
- 26 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for active adults with a recent ACL (knee ligament) tear who plan ACL reconstruction surgery using their own tendon. Knee injections of anakinra or saline are given before surgery.
- Age
- 18 to 35 years, with closed growth plates seen on X-ray.
- Sex
- Men and women can join (8 men and 8 women per group).
- Disease stage
- ACL injury confirmed by MRI within 2 weeks of presentation. People who do cutting and pivoting activities. Must choose bone-patellar tendon-bone (BTB) autograft ACL reconstruction within 45 days of injury. No posterior cruciate ligament injury, no more than grade 1 medial collateral ligament injury, no posterolateral corner injury on the same knee. A new meniscus injury at the same time is allowed.
- Earlier treatment
- No earlier surgery on the same knee. No cortisone injection into either knee within 3 months of injury. No earlier exposure to IL-1Ra. No other drug trial within the 4 weeks before injury.
Main reasons for not taking part
- Injury more than 2 weeks before enrollment, earlier injury to the same knee, or several knee ligaments injured
- Grade 3 or 4 cartilage injuries
- Allergy or bad reaction to anakinra, or active infection
- Bleeding disorder or current blood-thinning treatment
- Current cancer, inflammatory or rheumatic disease, weak immune system, or kidney failure
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- patients age 18 to 35 years with closed growth plates as visualized on plain radiographs who participate in cutting and pivoting activities
- we will enroll an equal number of men and women in each treatment group (16 total per group; 8 men, 8 women)
- study participants must have an MRI-confirmed ACL injury within 2 weeks of presentation
- must elect to undergo bone-patellar tendon-bone (BTB) autograft ACL reconstruction within 45 days of injury
- no clinical or MRI evidence of posterior cruciate ligament injury
- no more than grade 1 medial collateral ligament injury
- no concurrent posterolateral corner injury to the ipsilateral knee
Who cannot take part
- injury occurring more than 2 weeks prior to enrollment
- previous ipsilateral knee injury
- pre-existing or concurrent grade 3 or 4 chondral (cartilage) injuries
- previous ipsilateral knee surgery (meniscus tear, ACL tear, chondral injury, etc.)
- of note, concurrent acute meniscus injury is NOT an exclusion criteria
- prior exposure to IL-1Ra
- participation in another clinical drug trial within the 4 weeks before injury
- active infection
- known allergy or adverse reaction to anakinra
- history of any coagulopathy or current anti-coagulation therapy
- current malignancy
- current inflammatory/rheumatologic disease
- current renal failure
- multi-ligamentous knee injury
- intra-articular cortisone injection into either knee within 3 months of injury
- current immune-compromised state
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 35 years old?
Where in United States
- University of California, Los AngelesLos Angeles, United StatesContact: Thomas J. Kremen, M.D.Taking people
About the trial
What the trial wants to find out
Anterior cruciate ligament (ACL) injuries are extremely common. On average, 50% of individuals suffering an ACL injury will develop radiographic osteoarthritis (OA) 10 to 20 years after injury. Unfortunately, ACL reconstruction does not prevent risk of future OA.
Read full original descriptionShow less
Interleukin-1 (IL-1) levels in the human knee joint increase transiently after an ACL injury. In animal experiments, if interleukin-1 levels are increased in the joint, this alone causes arthritis to occur. Interleukin-1 receptor antagonist (IL-1Ra) is a naturally occurring inhibitor of IL-1. However, in ACL injuries the balance of these two proteins is disturbed transiently after injury, with the effects of IL-1 dominating this balance. In a large animal model of ACL injury, injection of IL-1Ra into the knee joint after ACL injury significantly decreased the amount of arthritis that was later observed. Thus, the investigators hypothesize that early injection of IL-1 inhibitor (IL-1Ra) into the knee joint of patients suffering recent ACL injury will decrease the incidence of cartilage damage later in life.
After appropriate IRB approval, a total of 32 active patients will be randomized into one of two treatment groups. Group 1 will receive removal of the knee joint fluid (aspiration of hemarthrosis) using a needle and syringe within 1 to 2 weeks of injury. Following aspiration of the knee joint, an injection of 5 milliliters (mls) of sterile saline (as a placebo control) will be administered. In addition, a second knee aspiration procedure and an injection of 5mls of sterile saline into the injured knee joint will be performed at 3 to 5 days after the initial injection. Group 2 will receive aspiration of the knee hemarthrosis as described in group 1 as well as intra-articular administration of 150mg (~5mls) of anakinra (rhIL-1Ra) within 1 to 2 weeks of ACL injury. In addition, a second knee aspiration and intra-articular administration of 150mg (~5mls) of anakinra (rhIL-1Ra) will be performed at 3 to 5 days after the initial injection. Thus, all patients in this randomized placebo-controlled trial will undergo two injection procedures prior to surgery.
Investigators will analyze subjects self-reported function and pain scores as well as urinary levels of cartilage breakdown products over time. Additionally, MRI studies will be used to compare MRI findings among patients in these 2 treatment groups. Urine samples will be obtain prior to surgery, at the time of surgery and at multiple time points after surgery (3, 6, 9, 12 and 24 months after surgery). Subjective outcome measure assessments (surveys) will be completed by participants prior to surgery and then again at 6, 9, 12 and 24 months post-operatively. MRI studies will be obtained at 1 year and 2 years following surgery. Additional, MRI studies at time points are optional and highly encouraged. These additional MRIs are at no cost to the patient.
The 2 groups in the trial
- ControlPlacebo, for comparison
Subjects will receive two injections of sterile saline after ACL injury, prior to surgery
Treatment: sterile saline injection
- Two doses AnakinraExisting treatment, for comparison
Subjects will receive two injections of anakinra after ACL injury, prior to surgery
Treatment: Anakinra injection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Biologic Therapy to Prevent Osteoarthritis After ACL Injury
- Plain-language title
- Anakinra knee injections after an ACL injury to help prevent later osteoarthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT03968913, who can take part
- Record updated
- 26 January 2026